SN102: a novel gene therapy for trigeminal neuralgia pain

Active Grant Awarded

Award ID
R43DE035747
Recipient
Awarding agency
Obligated
$338,115

Award facts

Assistance listing
93.121 Oral Diseases and Disorders Research
Completion date 16% complete
Place of performance
Baltimore, MD 21205, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Institute of Dental and Craniofacial Research awarded Sereneuro Therapeutics, Inc. $338,115 on Sep 23, 2026, under Assistance Listing 93.121, Oral Diseases and Disorders Research, to fund Phase I SBIR grant R43DE035747. The project optimizes SN102, a base-editing gene therapy for trigeminal neuralgia that installs a naturally occurring pain-dampening allele in peripheral pain-sensing neurons through a single local injection. Preliminary mouse osteoarthritis pain data show sustained efficacy for up to 10 weeks. The three aims are to quantify baseline SN102 efficacy in human induced pluripotent stem cell (iPSC)-derived nociceptors using the AAV-PHP.S capsid variant at varying multiplicities of infection, to conduct an in silico screen for nociceptor-specific regulatory elements that improve peripheral nervous system specificity, and to evaluate the top candidates across multiple iPSC-derived cell types. Performance runs from Sep 23, 2026 through Sep 22, 2027, with place of performance in Baltimore, MD 21205, USA.

Description

Abstract
Trigeminal neuralgia (TN) is a severe neuropathic pain condition affecting up to 15,000 new patients annually in the US. Current treatments are limited to medications with serious side effects and poor efficacy, or invasive neurosurgical procedures. SN102 is a novel gene therapy that utilizes base editing to install a naturally occurring pain-dampening allele specifically in peripheral pain-sensing neurons, offering the potential for safe and durable pain relief through a single treatment via local injection. Importantly, our preliminary data demonstrate SN102'S sustained efficacy in mouse osteoarthritis (OA) pain models for up to 10 weeks, providing strong proof-of- concept. The goal of this phase I sbir project is to optimize SN102'S delivery system for peripheral nervous system (PNS) specificity and demonstrate its efficacy in human induced pluripotent stem cell (IPSC)-derived nociceptors through the following specific aims. In aim 1, we will quantify the baseline efficacy of SN102 using AAV-PHP.S, an adeno-associated virus (AAV) capsid variant with enhanced peripheral neuron tropism, by examining calcium transients in edited IPSC-nociceptors at varying multiplicities of infection to establish the relationship between gene editor expression and functional outcomes. In aim 2, we will optimize SN102 for PNS specificity by conducting an in silico screen of nociceptor-specific regulatory elements. In aim 3, we will evaluate the top regulatory element candidates identified by the screen across multiple IPSC-derived cell types to confirm improved PNS specificity and efficacy of the optimized SN102 in human IPSC-nociceptors. Success in these studies will establish the foundational work for SN102 as a transformative therapy for TN patients and support advancement toward in vivo studies in a subsequent phase II sbir, with potential applications across multiple chronic pain conditions.

Quick answers

Who received award R43DE035747?

R43DE035747 was awarded to Sereneuro Therapeutics, Inc. by National Institute of Dental and Craniofacial Research (National Institutes of Health) on September 23, 2026.

How much is award R43DE035747 worth?

$338,115 has been obligated on R43DE035747.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award